The FDA has approved a label update for an inhaled insulin indicated for adults with type 1 or type 2 diabetes, according to ...
Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic ...
New Afrezza prescribing information outlines higher starting dose conversions for patients transitioning from mealtime ...
ORLANDO -- Most adults with type 1 diabetes switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) needed to increase their dose of the inhaled product to achieve ...
Medtronic said Monday it received 510 (k) clearance from the Food and Drug Administration for an app to connect its smart insulin pens with a glucose sensor made by Abbott.
Real-world data demonstrate that the MiniMed 780G system effectively controls glucose levels in users who do not administer ...
People with type 1 diabetes on higher daily doses of insulin faced a higher cancer risk, researchers found. Daily insulin dose was significantly linked with a higher risk for cancer (HR 4.13, 95% CI 1 ...
NovoLog (insulin aspart) is a prescription medication used to manage blood sugar levels in people with type 1 or type 2 diabetes. NovoLog dosage varies based on individual factors such as the type of ...
NovoLog is a mealtime (rapid-acting) insulin. It’s a brand-name form of insulin aspart. For type 1 diabetes, you’ll typically inject NovoLog before your meals throughout the day. For type 2 diabetes, ...
If you have certain types of diabetes, your doctor might suggest Fiasp as a treatment option for you. It’s a prescription drug used to control blood sugar levels in: adults and children with type 1 ...
Intranasal insulin may help reduce the incidence of postoperative delirium, cognitive dysfunction, and neuroinflammation in adults, a new meta-analysis suggests.
For information about Fiasp dosing, including the drug’s strength and how to take the medication, keep reading. For a comprehensive look at Fiasp, see this article. This article describes typical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results